Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, describes updates in the field of mesothelioma. Immunotherapy for patients who progress from chemotherapy have demonstrated mixed results, with the PROMISE-meso trial (NCT02991482) showing pembrolizumab to not be as efficacious as standard chemotherapy. However, nivolumab plus ipilimumab resulted in superior survival in the CONFIRM (NCT03063450) and CheckMate 743 (NCT02899299) trials. Prof. Popat additionally recommends immunotherapy in non-epithelioid mesothelioma in the first line setting. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
Updates in treating mesothelioma
Теги
Speaker: Sanjay PopatInstitution: The Royal Marsden NHS Foundation TrustEvent: BTOG 2022Format: InterviewSubject: Lung CancerSubject: MesotheliomaField: Immuno-OncologyField: TreatmentMedicines: PembrolizumabMedicines: AntibodiesMedicines: IpilimumabMedicines: NivolumabMedicines: Checkpoint InhibitorsTrial: PROMISE-mesoTrial: CONFIRMTrial: CheckMate 743NCT02991482NCT03063450NCT02899299immunotherapynon-epithelioid mesothelioma